The Cannigma

MARCH 25, 2021

In nursing school, I wrote my dissertation on the role of the nurse when caring for patients using cannabis therapeutically, knowing that nurses are often the first healthcare professional to whom patients disclose their cannabis use. I remain in awe of these patients to this day.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Food and Drug Administration (FDA) on December 1, 2021. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).

Clinical Trials 52

Clinical Trials Data Patients THC 52

The Cannigma

JANUARY 16, 2021

Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. Anonymized data also helps scientists better understand the cannabis plant and what products and chemical profiles are most effective for treating different conditions and symptoms.

Data 100

Data Research and Development Patients Strains 100

Cannabis Law Report

NOVEMBER 29, 2021

State legislators in 2021 enacted over 50 laws liberalizing marijuana policies in more than 25 states, according to a report issued today by the National Organization of the Reform of Marijuana Laws (NORML). 2021 was a significant year for marijuana policy reform. The law took effect on July 1, 2021. FULL REPORT. New Jersey.

Legislation 98

Legislation Patients Retail Access 98

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. Written by Dr. Meredith Fisher-Corn, MD , Editor-in-Chief at TheAnswerPage.com.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 11, 2021

The UK’s first and highest-rated medical cannabis clinic, Sapphire Medical Clinics , has today announced that it is reducing the cost of its consultations and appointments for patients enrolled through the Sapphire Access Scheme. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

TheAnswerPage

APRIL 9, 2021

What is the most common qualifying condition reported by medical marijuana patients? Currently and historically, the most common qualifying condition reported by medical marijuana patients is chronic pain. Qualifying Conditions of medical cannabis license holders in the United States. Boehnke et al. See Answer.

Chronic Pain 69

Chronic Pain Conditions Data Patients 69

Cannabis Law Report

JUNE 7, 2021

We increased the dosage to two doses of IGC-AD1 per day in Cohort 2, which was conducted from early February 2021 through mid-May 2021. The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. On December 15, 2021, the non-profit organization Freedom to Operate (FTO) filed a post-grant review filing to challenge a U.S.

Access 52

Access Patients Research and Development Treatment 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.)

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. ADDITIONAL INFORMATION.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

NOVEMBER 29, 2021

It has been shown that medicinal marijuana may help alleviate the symptoms of some conditions, provided that doctors keep a close eye on how much is taken and how often it’s used. As part of a prior study, these claims used data from states that legalized recreational marijuana usage by the middle of 2018.

Legalization 52

Legalization Research and Development Decriminalization Marijuana 52

Cannabis Law Report

JUNE 1, 2021

TORONTO, June 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – RYAH Group, Inc. The 5-year study is expected to cover tens of thousands of patients suffering from chronic pain, which makes it one of the largest and most ambitious research projects to be conducted in the plant-based treatment arena. About RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. We expect to report this data as it becomes available and after submission to the FDA. During the six months ended September 30, 2021, the Company raised approximately $4.1

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

NOVEMBER 26, 2021

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2021. On September 30, 2021, Can-Fite had approximately $13.3 Fortified Balance Sheet.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Veriheal

NOVEMBER 22, 2021

Headset , a leading cannabis data and market intelligence platform, recently conducted an audit of cannabis sales data around the United States—and the discoveries were interesting. To understand why medical patients might be purchasing more cannabis than recreational users, we have to look at buying behaviors.

Recreational 98

Recreational Data Dispensary Cannabis 98

Cannabis Law Report

JUNE 23, 2021

TORONTO, June 23, 2021 (GLOBE NEWSWIRE) — RYAH Group, Inc. Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. in real terms to £4.97

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

AUGUST 4, 2021

The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021. The Core Business delivered strong organic growth 13 in H1 2021 (17% year-on-year) despite some of Eurofins’ businesses remaining affected by lockdowns during H1 2021.

Business 105

Business Research and Development Environment Food 105

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. 1, 2020, and July 31, 2021—a 43% increase from the same period a year before. A 2019 study found that 76% of patients in the U.S. The Opioid Problem.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

JULY 19, 2021

July 19, 2021 07:58 ET | Source: Potbotics, Inc. Toronto, July 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — RYAH Group, Inc. The RYAH MD platform is designed for use by healthcare professionals to remotely monitor and control their patients’ dosing regimens with RYAH’s suite of dose-measuring products.

Therapy 76

Therapy Data Research and Development Events 76

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help. A primary headache, such as a migraine, is its own condition, and not caused by a separate condition.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

AUGUST 17, 2021

Improving Patient Outcomes with Real-time Feedback via Smart Inhalers and Portable and Lightweight Oxygen Concentrators for Increasing Home-Based Therapy is a Key Growth Opportunity. Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. The Strategic Imperative.

Research and Development 98

Research and Development Clinical Trials Concentrates Patients 98

The Cannigma

SEPTEMBER 13, 2021

In July, 2021, Israeli lawmakers rejected a bill that would have decriminalized recreational marijuana use. The Israeli government formally legalized medical marijuana in 1999, and by 2020 the number of registered patients reached a record high of over 70,000. Qualifying conditions for medical marijuana.

Legalization 97

Legalization Decriminalization Patients Cannabis 97

Cannabis Law Report

AUGUST 24, 2022

The third Cannabis as Medicine Survey (CAMS20) follows on from CAMS16 and CAMS18, and includes 1,600 people using medical cannabis between September 2020 and January 2021. People using illicit products were more likely to be treating mental health or sleep conditions. The results were recently published in Harm Reduction Journal.

Medicine 52

Medicine Legalization Chronic Pain Access 52

Cannabis Law Report

SEPTEMBER 1, 2022

AUSTIN, Texas, August 31, 2022 –( BUSINESS WIRE )–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). According to a 2021 Harm Reduction Journal study , 38.1% of cannabis patients.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Illinois News Joint

JANUARY 5, 2023

are the most since legalization in Illinois and a 12% increase from 2021 totals of $1,379,088,278.61 and 20% from 2021 totals of $669,084,410.12. For 2022, Illinois sold a total of 36,435,129 cannabis items, an increase of 20% from 2021. Recreational cannabis sales for 2021 totals included: January: $88,813,872.78.

Dispensary 73

Dispensary Recreational Cannabis Collective 73

The Cannigma

SEPTEMBER 15, 2022

As our body of research expands, new avenues of potential treatment emerge for conditions that were previously overlooked. People with autism often have comorbid diagnoses such as anxiety, depression, sleep disturbances, ADHD, epilepsy, allergies, autoimmune conditions, and gastrointestinal conditions. anxiety improved in 47.1%

Terpenes 91

Terpenes Strains Sleep THC 91

Veriheal

FEBRUARY 10, 2022

Medical cannabis patient enrollment is on the rise in South Dakota, and what better way to stay on top of things than by introducing a cloud-based platform? For the year 2022, patients who are interested in registering for South Dakota’s medical cannabis industry can apply with ease via the new fully digital internet-based program.

Programs 52

Programs Chronic Pain Patients Conditions 52

SpeedWeed

MARCH 6, 2021

Cannabis Voter Project (@Cannabis_Voter) March 3, 2021. Forcing patients to purchase more. Doing so, Pollara wrote, would effectively force a 50% to 150% tax on patients. It is also the one which produces the most and strongest medicinal effects for patients. NORML (@NORML) March 4, 2021. Feinstein nor Sen.

THC 52

THC Patients Law Chronic Pain 52

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Veriheal

AUGUST 3, 2021

Under the terms of the legislation, House Bill 1024 will extend cannabis curbside services and indefinitely eradicate the patient cap for actively serving caregivers. In addition to this, patients will be given the opportunity to acquire a 90-day supply of cannabis. Previously, registered patients were limited to a 30-day supply.

Legislation 98

Legislation Patients Supply Chain Dispensary 98

Cannabis Law Report

NOVEMBER 29, 2021

Published on November 30, 2021. Treatment-resistant depression – meaning patients have tried everything possible and did not find relief – is a harrowing condition affecting one in three people with depression – that’s a staggering one hundred million people worldwide for whom current depression treatments just don’t work.

Treatment 52

Treatment Clinical Trials Data Patients 52